Osteogenesis Imperfecta (01) Is an hereditary disease characterized by low bone mass, Increased bone fragility, short stature, and skeletal deformities, few treatment options are currently available. Nerldronate Is an amlno-blsphosphonate, licensed In Italy for the treatment of Ol and Paget's disease of bone. A characteristic property of nerldronate Is that It can be administered both Intravenously and Intramuscularly, providing an useful system for administration In homecare. Nerldronate appears to Increase Bone Mineral Density (BMD) In adults with Ol and reduces bone resorption by Inhibition of osteoclastic activity. Terlparatlde (recombinant 1-34 N terminal sequence of human parathyroid hormone) Is the first anabolic agent approved for the treatment of patients with osteoporosis and has been reported to Increase bone formation by stimulating osteoblast differentiation, osteoblast function, and survival. The results of this study showed a promising role of terlparatlde In the therapy of Ol type I.
Efficacy of teriparatide vs neridronate in adults with osteogenesis imperfecta type I: A prospective randomized international clinical study / Leall, Paolo Tranqullll; Balsano, Massimo; Maestrettl, Glanluca; Brusonl, Matteo; Amorese, Veronica; Clurlla, Emanuele; Andreozzl, Matteo; Cagglarl, Glanflllppo; Doria, Carlo. - In: CLINICAL CASES IN MINERAL AND BONE METABOLISM. - ISSN 1724-8914. - 14:2(2017), pp. 153-156.